THE EFFECTS OF TIRZEPATIDE ON LIPOMA, LIPEDEMA, AND FEMALE HORMONES: IMPACT ON THE MENSTRUAL CYCLE
DOI:
https://doi.org/10.63330/aurumpub.061-026Keywords:
Tirzepatide, Dual GLP-1/GIP agonist, Lipoma, Lipedema, Female hormones, Menstrual cycle, Insulin resistanceAbstract
Tirzepatide is a dual GLP-1 and GIP receptor agonist approved for type 2 diabetes and weight management, possessing broad metabolic and anti-inflammatory effects. This article analyzes its effects on lipomas, lipedema, and the female hormonal axis, including its impact on the menstrual cycle. It concludes that the medication does not alter or reduce lipomas but significantly improves symptoms, volume, and pain associated with lipedema. Although it does not act directly on sex hormones, it promotes indirect changes—through improved insulin sensitivity and reduced fat mass—that can regularize irregular cycles or cause transient adjustments. Its use for these conditions is complementary and off-label, requiring multidisciplinary management.
Downloads
References
1. MDPI Int J Mol Sci. 2025;26(21):10741 – Tirzepatida como terapia modificadora no lipedema
2. Natural Cycles & PeptidesExplorer. 2026 – Alterações menstruais com agonistas GLP-1/GIP
3. PMC 2025 – Interação entre lipedema, resistência insulínica e tirzepatida
4. SURMOUNT-1 a 4 – Ensaios clínicos de perda ponderal e perfil metabólico
5. Diretrizes SBEM/FEBRASGO 2025 – Uso de agonistas incretínicos em mulheres
6. FDA/ANVISA 2026 – Informações de bula e segurança reprodutiva
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
